心血管康复医学杂志
心血管康複醫學雜誌
심혈관강복의학잡지
JOURNAL OF CARDIOVASCULAR REHABILITATION MEDICINE
2014年
3期
327-330
,共4页
红细胞生成素,重组%心力衰竭,充血性%肾功能衰竭,慢性
紅細胞生成素,重組%心力衰竭,充血性%腎功能衰竭,慢性
홍세포생성소,중조%심력쇠갈,충혈성%신공능쇠갈,만성
Erythropoietin,recombinant%Heart failure,congestive%Kidney failure,chronic
目的:观察重组人促红细胞生成素(rhEPO)治疗心力衰竭合并慢性肾脏病患者的临床疗效。方法:选择84例心力衰竭合并肾功能不全的患者,采用随机数字表的方法分为常规治疗组(42例)和 rhEPO组(42例,在常规治疗基础上加用 rhEPO),治疗12周后,对比两组心脏超声及肾功能。结果:与常规治疗组比较, rhEPO组左室舒张末期内径[LVEDd,(6.12±0.67)mm比(5.01±0.54)mm]显著减小,左室射血分数[LVEF,(37.2±10.3)%比(45.4±11.4)%]和左室短轴缩短率[LVFS,(19.6±4.3)%比(24.5±3.8)%]显著提高,24h尿蛋白定量[(0.76±0.1)g比(0.24±0.09)g]、24h尿微量白蛋白[(319.6±39.6)mg比(107.3±26.7) mg]、血尿素氮[(10.3±1.9)mmol/L 比(6.2±1.5)mmol/L]、血肌酐[(97.2±16.8)μmol/L 比(79.3±15.7)μmol/L]显著改善(P均<0.01)。结论:重组人促红细胞生成素可显著改善心力衰竭合并肾功能不全患者的心、肾功能。
目的:觀察重組人促紅細胞生成素(rhEPO)治療心力衰竭閤併慢性腎髒病患者的臨床療效。方法:選擇84例心力衰竭閤併腎功能不全的患者,採用隨機數字錶的方法分為常規治療組(42例)和 rhEPO組(42例,在常規治療基礎上加用 rhEPO),治療12週後,對比兩組心髒超聲及腎功能。結果:與常規治療組比較, rhEPO組左室舒張末期內徑[LVEDd,(6.12±0.67)mm比(5.01±0.54)mm]顯著減小,左室射血分數[LVEF,(37.2±10.3)%比(45.4±11.4)%]和左室短軸縮短率[LVFS,(19.6±4.3)%比(24.5±3.8)%]顯著提高,24h尿蛋白定量[(0.76±0.1)g比(0.24±0.09)g]、24h尿微量白蛋白[(319.6±39.6)mg比(107.3±26.7) mg]、血尿素氮[(10.3±1.9)mmol/L 比(6.2±1.5)mmol/L]、血肌酐[(97.2±16.8)μmol/L 比(79.3±15.7)μmol/L]顯著改善(P均<0.01)。結論:重組人促紅細胞生成素可顯著改善心力衰竭閤併腎功能不全患者的心、腎功能。
목적:관찰중조인촉홍세포생성소(rhEPO)치료심력쇠갈합병만성신장병환자적림상료효。방법:선택84례심력쇠갈합병신공능불전적환자,채용수궤수자표적방법분위상규치료조(42례)화 rhEPO조(42례,재상규치료기출상가용 rhEPO),치료12주후,대비량조심장초성급신공능。결과:여상규치료조비교, rhEPO조좌실서장말기내경[LVEDd,(6.12±0.67)mm비(5.01±0.54)mm]현저감소,좌실사혈분수[LVEF,(37.2±10.3)%비(45.4±11.4)%]화좌실단축축단솔[LVFS,(19.6±4.3)%비(24.5±3.8)%]현저제고,24h뇨단백정량[(0.76±0.1)g비(0.24±0.09)g]、24h뇨미량백단백[(319.6±39.6)mg비(107.3±26.7) mg]、혈뇨소담[(10.3±1.9)mmol/L 비(6.2±1.5)mmol/L]、혈기항[(97.2±16.8)μmol/L 비(79.3±15.7)μmol/L]현저개선(P균<0.01)。결론:중조인촉홍세포생성소가현저개선심력쇠갈합병신공능불전환자적심、신공능。
Objective:To observe clinical therapeutic effect of recombinant human erythropoietin (rhEPO)on pa-tients with heart failure complicated chronic kidney disease.Methods:A total of 84 patients with heart failure com-plicated renal insufficiency were selected.They were divided into routine treatment group (n=42)and rhEPO group (n=42,received rhEPO based on routine treatment)according to random number table method.Echocardiographic examination results and renal function were compared between two groups after 12-week treatment.Results:Com-pared with routine treatment group,there were significant rise in left ventricular ejection fraction [LVEF,(37.2± 10.3)% vs.(45.4 ± 11.4)%]and left ventricular fractional shortening [LVFS,(19.6 ± 4.3)% vs.(24.5 ± 3.8)%],and significant reductions in left ventricular end-diastolic diameter [LVEDd,(6.12±0.67)mm vs.(5.01 ±0.54)mm],24h urinary protein [(0.76±0.1)g vs.(0.24±0.09)g],24h urine microalbumin [(319.6±39.6) mg vs.(107.3±26.7)mg],blood urea nitrogen [(10.3±1.9)mmol/L vs.(6.2±1.5)mmol/L]and serum creati-nine [(97.2±16.8)μmol/L vs.(79.3±15.7)μmol/L]in rhEPO group,P<0.01 all.Conclusion:Recombinant human erythropoietin could significantly improve heart,renal function in patients with heart failure complicated re-nal insufficiency.